If you or a loved one is a diabetic over 50 who has suffered a heart attack, there's an opportunity to obtain a potentially lifesaving therapy AT NO CHARGE. Dr. Dana Cohen describes the TACT2 trial, a multi-million dollar government-sponsored study to evaluate the effectiveness of chelation therapy. What is chelation? What is its history? How did the first TACT study demonstrate its effectiveness? Why was it greeted with skepticism by the medical establishment? Why have only integrative doctors been eager to embrace chelation?
Second study will focus on benefits of removing toxic metal pollutants in patients with diabetes and a prior heart attack
Dana G. Cohen, MD has been named a participating clinical site for the second Trial to Assess Chelation Therapy (TACT2). TACT2 will examine the use of intravenous chelation treatments in combination with oral vitamins in diabetic patients with a prior heart attack to determine if they reduce recurrent heart episodes, such as heart attacks, stroke, death, and others, by removing toxins from the blood.
Funding for TACT2 was announced in September of 2016 when The National Center for Complementary and Integrative Health (NCCIH) of the National Institutes of Health (NIH) awarded $37M to initiate the trial. The trial is also co-funded by the National Heart, Lung and Blood Institute, the National Institute of Diabetes and Digestive and Kidney Diseases and the National Institute of Environmental Health Sciences.
Chelation is a process by which a medication, such as edetate d...